AC Immune Stock Price, News & Analysis

AC Immune SA (NASDAQ: ACIU), a leader in precision medicine for neurodegenerative diseases, will participate in the SVB Leerink 11th Annual Global Healthcare Conference from February 14-18, 2022. CEO Prof. Andrea Pfeifer will engage in a fireside chat on February 16 at 8:00 am ET, discussing the company’s strategic plans and seven upcoming clinical readouts. The event will be available via webcast on their website. AC Immune is advancing a robust pipeline with ten therapeutic and three diagnostic candidates, focusing on diseases like Alzheimer’s and Parkinson’s.

AC Immune SA (NASDAQ: ACIU) has received approximately USD 1.5 million in grants from The Michael J. Fox Foundation for Parkinson’s Research. This funding will support the development of innovative small molecules aimed at inhibiting alpha-synuclein (a-syn) aggregation and NLRP3 inflammasome activation in Parkinson’s disease. The grants enhance AC Immune's research capabilities and expand its portfolio, including an anti-a-syn vaccine and a novel imaging tracer, showcasing its commitment to precision medicine in treating neurodegenerative diseases.

AC Immune SA (NASDAQ: ACIU) presented promising interim Phase 1b/2a trial results for ACI-35.030, a vaccine targeting pathological tau in Alzheimer's disease, at the 14th CTAD conference. The data shows significant antibody induction against pTau and its aggregated forms, indicating strong immunogenicity. Safety data revealed no clinically relevant concerns. The trial has expanded to 24 participants to support late-stage development. The results suggest potential for early intervention in Alzheimer's treatment, with further data expected from the ongoing study.

AC Immune announced positive topline results from its Phase 2 Lauriet study of semorinemab, an anti-Tau monoclonal antibody for mild-to-moderate Alzheimer’s disease (AD). The study achieved a 43.6% reduction in cognitive decline at week 49 as measured by the ADAS-Cog11 scale, confirming the treatment's efficacy across various subgroups. However, it did not meet the second co-primary endpoint related to daily living activities. Safety results were positive, indicating semorinemab had an acceptable safety profile with no unexpected adverse events. The ongoing open-label study aims to further assess long-term effects.

AC Immune SA (NASDAQ: ACIU) reported progress in its clinical trials and financial results for Q3 2021, achieving its first positive cognitive results for a Tau-targeting monoclonal antibody in Alzheimer’s disease. The Phase 2 Lauriet trial showed a statistically significant 43.6% reduction in cognitive decline. The company enhanced its portfolio through the acquisition of an alpha-synuclein vaccine candidate. Financially, AC Immune holds CHF 188.6 million in cash, sufficient to fund operations through Q1 2024, despite a net loss of CHF 15.9 million for the quarter.

AC Immune SA (NASDAQ: ACIU), a biopharmaceutical company based in Switzerland, is extending its research partnership with the University of Pennsylvania focused on TDP-43 proteinopathies. The collaboration aims to explore the mechanisms of TDP-43 misfolding and cell-to-cell transmission, which are important in neurodegenerative diseases like ALS and Alzheimer's. The initial research demonstrated distinct TDP-43 species affecting disease progression. AC Immune is also advancing its lead anti-TDP-43 antibody and developing a PET tracer for diagnostics.

AC Immune SA (NASDAQ: ACIU) announced the presentation of new data on its Alzheimer’s disease candidates at the upcoming Clinical Trials on Alzheimer’s Disease (C-TAD) Conference in Boston from November 9-12, 2021. Highlights include:

• Semorinemab: Phase 2 trial results presented on November 10.
• ACI-35.030: Interim Phase 1b/2a data on safety presented on November 12.
• ACI-24: Phase 2 study results from November 9-12.

This continues AC Immune's focus on neurodegenerative diseases with a pipeline of clinical candidates.

AC Immune (NASDAQ: ACIU) has appointed Dr. Monica Shaw and Prof. Monika Bütler to its Board of Directors following an extraordinary general meeting (EGM). They replace Mr. Martin Velasco and Dr. Peter Bollmann. Dr. Shaw brings extensive drug development experience, while Prof. Bütler contributes expertise in economics and public policy. Both express enthusiasm about advancing AC Immune's mission in precision medicine for neurodegenerative diseases like Alzheimer’s. The company has a strong pipeline and partnerships that may enhance shareholder value.

AC Immune SA (NASDAQ: ACIU) announced participation in the Jefferies London Healthcare Conference on November 18-19, 2021. CEO Prof. Andrea Pfeifer will lead a fireside chat discussing the company’s corporate strategy, focusing on precision medicine and ongoing clinical trials, including the Lauriet Phase 2 trial of semorinemab for Alzheimer’s disease. The fireside chat will be available on-demand during the conference and later on AC Immune’s website. The company continues to advance its pipeline aimed at treating neurodegenerative diseases.